首页> 外文期刊>The Lancet >Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.
【24h】

Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.

机译:面部基底细胞癌的手术切除与Mohs显微照相术:随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Rates of recurrence of facial basal-cell carcinoma are consistently lower after Mohs' micrographic surgery (MMS) than after other treatments, such as surgical excision (SE). However, MMS is more time-consuming and therefore more expensive than SE. We investigated the types of facial basal-cell carcinomas in which MMS was more effective than SE. METHODS: 408 primary and 204 recurrent facial carcinomas (374 and 191 patients, respectively) were analysed separately in this prospective randomised study. Patients were assigned SE or MMS (each 204 primary, 102 recurrent), and received treatment at two hospitals in the Netherlands. The primary outcome was recurrence of carcinoma. Analysis was by intention to treat. FINDINGS: Of the basal-cell carcinomas included in the trial, 397 primary (198 MMS, 199 SE) and 201 recurrent (99, 102) tumours were actually treated. Of patients with primary carcinomas, 21 had both MMS and SE on different tumours. Nine with recurrent carcinomas had both treatments on different skin tumours. 66 primary and 13 recurrent carcinomas were lost to follow-up. Of the primary carcinomas, five (3%) recurred after SE compared with three (2%) after MMS during 30 months of follow-up. Of the recurrent carcinomas, three (3%) recurred after SE and none after MMS during 18 months of follow-up. Four recurrent carcinomas randomly assigned to the SE group were treated with MMS. Although both differences favoured MMS, they were not significant (primary, difference 1% [95% CI -2.5% to 3.7%], p=0.724; recurrent, 3.2% [-2.0% to 5.0%], p=0.119). Total operative costs of MMS were higher than those of SE (primary 405.79 Euros vs 216.86 Euros, recurrent 489.06 Euros vs 323.49 Euros; both p<0.001). INTERPRETATION: No definitive conclusion on recurrence rates of primary or recurrent basal-cell carcinomas is yet possible. Although recurrence rates were lower after MMS than after SE, the differences were not significant.
机译:背景:在进行Mohs显微外科手术(MMS)后,面部基底细胞癌的复发率始终低于其他方法,例如手术切除(SE)。但是,MMS比SE更耗时,因此更昂贵。我们调查了其中MMS比SE更有效的面部基底细胞癌的类型。方法:这项前瞻性随机研究分别分析了408例原发性和204例复发性面部癌(分别为374例和191例)。患者被指定为SE或MMS(每例204例,复发102例),并在荷兰的两家医院接受了治疗。主要结果是癌的复发。分析是按意向进行的。结果:在该试验中所包括的基底细胞癌中,实际治疗了397例原发性(198 MMS,199 SE)和201例复发性(99,102)肿瘤。在原发性癌症患者中,有21名同时具有不同肿瘤的MMS和SE。九例复发性癌症在不同的皮肤肿瘤上都有两种治疗方法。 66例原发性癌和13例复发性癌丢失了随访。在30个月的随访中,原发癌中有5例(3%)在SE后复发,而MMS术后有3例(2%)复发。在18个月的随访中,复发的癌中有3例(3%)在SE后复发,而在MMS之后没有复发。用MMS治疗随机分配到SE组的4例复发癌。尽管两种差异都支持MMS,但它们并不显着(主要差异为1%[95%CI -2.5%至3.7%],p = 0.724;经常性差异为3.2%[-2.0%至5.0%],p = 0.119)。 MMS的总手术成本高于SE(主要405.79欧元vs 216.86欧元,经常性489.06欧元vs 323.49欧元;两者均p <0.001)。解释:关于原发性或复发性基底细胞癌的复发率尚无确切结论。尽管MMS后的复发率低于SE后的复发率,但差异并不显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号